Overview
- Patients prescribed GLP-1 receptor agonists had a five-year mortality of 15.5% versus 37.1% among non-users in UC Health records.
- The association persisted after adjusting for age, body mass index, cancer severity, and other health conditions.
- The largest survival advantage appeared in patients with a BMI over 35, suggesting a link to obesity-related metabolic pathways.
- The analysis included drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) and was published November 11 in Cancer Investigation.
- Researchers caution the study cannot prove causation and propose trials to test whether benefits stem from direct anti-tumor effects or improved metabolic health.